Wednesday, August 30, 2017 10:15 PM ET
Insider Sales at CRISPR Therapeutics (CRSP) Extends the Selling Trend of Last Quarter
In SEC filings today CRISPR Therapeutics revealed two insiders — Kurt von Emster, Director, and Dr Samarth Kulkarni, Officer — sold 115,165 shares in the company having a market value of approximately $2,286,899. There have been 2 insiders with buy/sell transactions in the past 90 days prior to these filings. All of these trades have been sales resulting in the sale of 577,444 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 692,609 shares and have averaged 173,152 shares per transaction over this time period.
The number of insider buy/sell trades at CRISPR Therapeutics is higher than that of the 181 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 178 buy/sell trades during this period for an average of 1.0 transactions per company. However, the number of shares traded per transaction by CRISPR Therapeutics insiders is lower than its peers. Within the peer group there were 7,836,546 shares purchased and 41,413,870 shares sold with company insiders disposing of 188,637 shares on average over this time period.
The data used in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Today’s Insider Activity
* Kurt von Emster, Director, sold 88,011 shares
* Dr Samarth Kulkarni, Officer, sold 27,154 shares
Using proprietary artificial intelligence methods, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.